Claims for Patent: 9,993,495

Summary for Patent: 9,993,495

Title:	Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
Abstract:	The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.
Inventor(s):	Guiducci; Cristiana (Albany, CA), Coffman; Robert L. (Portola Valley, CA)
Assignee:	Dynavax Technologies Corporation (Berkeley, CA)
Application Number:	15/162,535
Patent Claims:	1. A method of treating cancer of the lung in a mammalian subject in need thereof, the method comprising administering to the subject an effective amount of a polynucleotide by intrapulmonary delivery, wherein the polynucleotide consists of the sequence of: 5'-TCGTAACGTTCGAACGTTCGANx-3' (SEQ ID NO:2), wherein x is 0, 1 or 2, each N is A, C or T, and wherein at least one internucleotide linkage is a phosphorothioate linkage. 2. The method of claim 1, wherein the polynucleotide consists of SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9. 3. The method of claim 1, wherein the polynucleotide is double stranded. 4. The method of claim 1, wherein all of the internucleotide linkages are phosphorothioate linkages. 5. The method of claim 1, wherein the subject has a primary cancer selected from the group consisting of primary lung cancer and extrapulmonary cancer. 6. The method of claim 1, wherein the cancer of the lung is primary lung cancer. 7. The method of claim 6, wherein the primary lung cancer is non-small-cell lung carcinoma (NSCLC) or small-cell lung carcinoma (SCLC). 8. The method of claim 1, wherein the cancer of the lung is metastatic cancer to the lung. 9. The method of claim 8, wherein the metastatic cancer is a metastasis of a primary cancer selected from the group consisting of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, melanoma, pancreatic cancer, prostate cancer, and ovarian cancer. 10. The method of claim 1, wherein the mammalian subject is a human. 11. The method of claim 1, further comprising administering an effective amount of a second therapeutic agent to the subject. 12. The method of claim 11, wherein the second therapeutic agent comprises a chemotherapeutic agent selected from the group consisting of actinomycin, afatinib, alectinib, asparaginase, azacitidine, azathioprine, bicalutamide, bleomycin, bortezomib, camptothecin, carboplatin, capecitabine, certinib, cisplatin, chlorambucil, crizotinib, cyclophosphamide, cytarabine, daunorubicin, docetaxel, doxifluridine, doxorubicin, erlotinib, epirubicin, epothilone, etoposide, fludarabine, flutamine, fluorouracil, gefitinib, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, irinotecan, lapatinib, letrozole, mechlorethamine, mercaptopurine, methotrexate, mitomycin, mitoxantrone, octreotide, oxaliplatin, paclitaxel, pemetrexed, raltitrexed, sorafenib, sunitinib, tamoxifen, temozolomide, teniposide, tioguanine, topotecan, valrubicin, vinblastine, vincristine, vindesine, vinorelbine, and combinations thereof. 13. The method of claim 12, wherein the chemotherapeutic agent comprises one or more of the group consisting of cyclophosphamide, doxorubicin, and vincristine. 14. The method of claim 12, wherein the chemotherapeutic agent comprises one or more of the group consisting of mitomycin, vindesine and cisplatin. 15. The method of claim 12, wherein the chemotherapeutic agent comprises one or both of the group consisting of cisplatin and vinorelbine. 16. The method of claim 12, wherein the chemotherapeutic agent comprises one or both of the group consisting of cisplatin, etoposide and ifosfamide. 17. The method of claim 11, wherein the second therapeutic agent is an antagonist of an inhibitory immune checkpoint molecule. 18. The method of claim 17, wherein the inhibitory immune checkpoint molecule is selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4(CD152), LAG-3, TIM-3, TIGIT, IL-10, and TGF-beta. 19. The method of claim 17, wherein the inhibitory immune checkpoint molecule is indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO). 20. The method of claim 11, wherein the second therapeutic agent is an agonist of an immune stimulatory molecule. 21. The method of claim 20, wherein the immune stimulatory molecule is selected from the group consisting of CD27, CD40, OX40 (CD134), GITR, CD137, CD28 and ICOS (CD278). 22. The method of claim 11, wherein the second therapeutic agent comprises an antibody, fragment or derivative thereof. 23. The method of claim 5, further comprising one or both of resecting the primary cancer and administering radiation therapy. 24. The method of claim 11, wherein the effective amount of the polynucleotide and the effective amount of the second therapeutic agent together result in a synergistic effect against the cancer of the lung. 25. The method of claim 11, wherein the effective amount of the polynucleotide and the effective amount of the second therapeutic agent together result in an additive effect against the cancer of the lung. 26. The method of claim 11, wherein the effective amount of the polynucleotide and the effective amount of the second therapeutic agent together result in a cooperative effect against the cancer of the lung. 27. The method of claim 5, wherein treating cancer of the lung comprises one or more of the following: (a) increasing survival time of the subject; (b) reducing volume of the primary cancer; (c) retarding growth of the primary cancer; (d) reducing number of metastatic tumors; (e) reducing volume of metastatic tumors; and (f) retarding growth of metastatic tumors. 28. The method of claim 1, wherein treating cancer of the lung comprises inducing secretion in the lung of one or more cytokines selected from the group consisting of chemokine CC motif ligand 2 (CCL2), chemokine CXC motif ligand 10 (CXCL10), interferon-alpha (IFN-.alpha.), interferon-gamma (IFN-.gamma.), interleukin-1alpha (IL-1.alpha.), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12 p70 (IL-12 p70), granulocyte colony-stimulating factor (GCSF), and tumor necrosis factor-alpha (TNF-.alpha.). 29. The method of claim 1, wherein treating cancer of the lung does not result in polynucleotide-induced toxicity of the lung of such severity that repeated administration of the polynucleotide is contraindicated. 30. The method of claim 1, wherein treating cancer of the lung does not result in polynucleotide-induced flu-like symptoms of such severity that repeated administration of the polynucleotide is contraindicated, wherein the flu-like symptoms comprise one or more of the group consisting of fever, headache, chills, myalgia and fatigue. 31. A method of treating cancer in a mammalian subject in need thereof, comprising: administering a pharmaceutical composition to the subject in an amount sufficient to treat cancer in the subject, wherein the pharmaceutical composition comprises an isolated polynucleotide and pharmaceutically acceptable excipient, and the polynucleotide consists of the sequence of: 5'-TCGTAACGTTCGAACGTTCGANx-3' (SEQ ID NO:2), wherein x is 0, 1 or 2, each N is A, C or T, and wherein at least one internucleotide linkage is a phosphorothioate linkage. 32. The method of claim 31, wherein the pharmaceutical composition is administered to the subject by intrapulmonary administration. 33. The method of claim 32, wherein the intrapulmonary administration involves use of a device selected from the group consisting of a nebulizer, a metered-dose inhaler, a sprayer, and a dry-powder inhalation device. 34. The method of claim 31, wherein the pharmaceutical composition is administered by injection through a route selected from the group consisting of intravenous, intramuscular, and subcutaneous. 35. The method of claim 31, wherein the polynucleotide consists of SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9.

Details for Patent 9,993,495

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2035-05-29